Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
429 Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.